Midatech pulls off a $50M IPO; Valeant takes an M&A breather;

@FierceBiotech: Bluebird posts more promising results with its rare disease therapy. Story | Follow @FierceBiotech

@DamianFierce: So the billionaire Russian oligarch who bought Watson's Nobel medal for $4.1 million is giving it back because hey. More | Follow @DamianFierce

> Nanomedicine developer Midatech priced a £32 million ($50 million) London IPO, immediately spending some of its proceeds to acquire Q Chip, a Welsh firm with a proprietary technology for sustained-release formulation. News

> PaxVax's cholera vaccine met its primary endpoint in a Phase III trial, the company said, setting the stage for an FDA application in mid-2015. Story

> Valeant Pharmaceuticals ($VRX), famed for its serial acquisitions, is planning to take a break from dealmaking to focus on its mounting debt, according to Reuters. Article

Medical Device News

@FierceMedDev: ICYMI yesterday: Edwards gains option to acquire startup CardioKinetix in $50M financing. Article | Follow @FierceMedDev

@EmilyWFierce: Stryker's OtisMed to pay more than $80M to settle DOJ case over knee replacement surgical devices. Story | Follow @EmilyWFierce

> Eurofins Scientific snaps up Boston Heart Diagnostics for $140M. Story

> Brain sensors go wireless in Brown University study. More

> Edwards looks to TAVR to convince Wall Street it can go higher after doubling in 2014. Article

Pharma News

@FiercePharma: Did Merck pay $3B too much for Cubist? Analysts weigh impact of Cubicin patent loss. Story | Follow @FiercePharma

@CarlyHFierce: AbbVie's Humira competition begins with Cadila's biosimilar launch in India. More | Follow @CarlyHFierce

> Long-term painkiller use on the rise, with more patients taking dangerous combos. Story

> J&J discount offer wins NICE over to new use for Stelara. Article

> Valeant temporarily swears off dealmaking to cut debt--and prove it's not desperate. News

Biotech Research News

> Epizyme showcases a successful preclinical lymphoma program for third target. More

> MicroRNA holds clues to predicting progression-free myeloma survival. Report

> New malaria drug unleashes an immune system assault on infected cells. Story

> Could alpha secretase offer a better approach to fighting Alzheimer's? More

> PKCƐ pathway offers a new line of attack against cancer cells. Article

Pharma Manufacturing News

> India's Zydus Cadila finds blood pressure med has embedded brown spots. Story

> Ferring preps for first U.S. plant opening as it moves to New Jersey campus. More

> FDA notches a win after Tennessee compounder pleads guilty. Report

> Meda drops Recipharm contract; plant may be forced to close. Story

> Daewoong inks deal to build $188M facility in South Korea. Article

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.